Worldwide focus on Covid-19 means a ‘minor issue’ is getting media attention, experts say
Australia’s drug regulator, the Therapeutic Goods Administration, has dismissed questions raised about “outdated information” in AstraZeneca vaccine data by the US Data and Safety Monitoring Board.
On Monday AstraZeneca released interim results from its phase 3 Covid-19 vaccine clinical trials which showed 100% efficacy against severe or critical disease and hospitalisation. It showed 80% efficacy in those aged 65 years and over and, overall, had 79% efficacy at preventing symptomatic Covid-19. These results were based on 32,449 participants.
